Abstract
Mass vaccination is effective in reducing SARS-CoV-2 infections among vaccinated individuals. However, it remains unclear how effectively Covid-19 vaccines prevent people from spreading the virus to their close contacts in real-world circumstances. Here, using nationwide administrative datasets on SARS-CoV-2 infections, vaccination records, demographics, and unique household IDs, we provide evidence about the direct and indirect effectiveness of Covid-19 vaccines in reducing infections among vaccinated individuals and their unvaccinated household members. Our estimates for adults imply indirect effectiveness of 8.7% (95% CI: -28.9 to 35.4) two weeks and 42.9% (95% CI: 22.3 to 58.1) 10 weeks after the first dose. We find that the indirect effect of Covid-19 vaccines is smaller and less precise for unvaccinated children aged between 3 to 18 years than for adults. These results provide household-level evidence that vaccines do not only protect vaccinated individuals but provide indirect protection to unvaccinated individuals in a real-world setting.
Competing Interest Statement
Dr. Kortelainen declares a grant to his employer, but no personal support or financial relationship, from Pfizer during the conduct of the study. The other authors have no conflict of interest to declare.
Funding Statement
This research was supported by the InFLAMES and INVEST Flagship Programmes of the Academy of Finland. Dr. Kortelainen declares a grant to his employer, but no personal support or financial relationship, from Pfizer during the conduct of the study. The other authors have no conflict of interest to declare.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The final data provided to the authors was de-identified. The research does not constitute human subjects research. Ethical approval was waived by the Institutional Review Board of the Finnish Institute for Health and Welfare (IRB: 00007085).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
21
Blogs/Media
Author Videos